Following the Zika outbreak in Latin America in late 2015, a number of pharmaceutical companies have stepped up their vaccine research efforts against a virus that has now been scientifically determined as the cause of microcephaly and other severe brain defects in babies. But will a product be able to reach the market soon enough to have an impact on the current outbreak?